This is a summary of the European public assessment report (EPAR) for Neuraceq. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Neuraceq.
For practical information about using Neuraceq, patients should read the package leaflet or contact their doctor or pharmacist.
Neuraceq : EPAR - Summary for the public (PDF/156.87 KB)
First published: 11/03/2014
Last updated: 01/07/2016
Neuraceq : EPAR - Risk-management-plan summary (PDF/60.77 KB)
First published: 13/05/2014
Last updated: 18/07/2019
|Agency product number||
|International non-proprietary name (INN) or common name||
|Therapeutic area (MeSH)||
|Anatomical therapeutic chemical (ATC) code||
Life Radiopharma Berlin GmbH
|Date of issue of marketing authorisation valid throughout the European Union||
01/09/2022 Neuraceq - EMEA/H/C/002553 - II/0038
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
This medicinal product is for diagnostic use only.
Neuraceq is a radiopharmaceutical indicated for Positron Emission Tomography (PET) imaging of β amyloid neuritic plaque density in the brains of adult patients with cognitive impairment who are being evaluated for Alzheimer’s disease (AD) and other causes of cognitive impairment. Neuraceq should be used in conjunction with a clinical evaluation.
A negative scan indicates sparse or no plaques, which is not consistent with a diagnosis of AD.